Skip to content
10-Q

Quarterly Report

BRIACELL THERAPEUTICS CORP. BCTX BCTXL BCTXZ

0001493152-26-009557

← back to feed
Filed
Mar 10, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Mar 10, 2026 7.25M sh
Shares Diluted Q2 2026 · Jan 31, 2026 2.8M sh
Shares Diluted Q2 2026 · Jan 31, 2026 2.34M sh
Shares Diluted restated Q2 2026 · Jan 31, 2025 269.96K sh
Shares Diluted restated Q2 2026 · Jan 31, 2025 222.5K sh
Operating Cash Flow Q2 2026 · Jan 31, 2026 −$15.67M
Operating Cash Flow Q2 2026 · Jan 31, 2025 −$12.88M
Cash And Equivalents Q2 2026 · Jan 31, 2026 $29.9M
Cash And Equivalents Q2 2026 · Jul 31, 2025 $10.49M
Current Liabilities Q2 2026 · Jan 31, 2026 $3.19M
Current Liabilities Q2 2026 · Jul 31, 2025 $3.98M
Current Assets Q2 2026 · Jan 31, 2026 $32.18M
Current Assets Q2 2026 · Jul 31, 2025 $19.93M
Total Assets Q2 2026 · Jan 31, 2026 $33.59M
Total Assets Q2 2026 · Jul 31, 2025 $21.65M
Eps Diluted Q2 2026 · Jan 31, 2026 −$2.58
Eps Diluted Q2 2026 · Jan 31, 2026 −$6.58
Eps Diluted restated Q2 2026 · Jan 31, 2025 −$23.31
Eps Diluted restated Q2 2026 · Jan 31, 2025 −$54.35
Eps Basic Q2 2026 · Jan 31, 2026 −$2.58
Eps Basic restated Q2 2026 · Jan 31, 2025 −$23.31
Eps Basic restated Q2 2026 · Jan 31, 2025 −$54.35
Sga Expense Q2 2026 · Jan 31, 2026 $1.48M
Sga Expense Q2 2026 · Jan 31, 2026 $3.12M
Sga Expense Q2 2026 · Jan 31, 2025 $1.48M
Sga Expense Q2 2026 · Jan 31, 2025 $2.97M
Rd Expense Q2 2026 · Jan 31, 2026 $6.05M
Rd Expense Q2 2026 · Jan 31, 2026 $12.74M
Rd Expense Q2 2026 · Jan 31, 2025 $5.68M
Rd Expense Q2 2026 · Jan 31, 2025 $9.35M
Net Income Q2 2026 · Jan 31, 2026 −$7.22M
Net Income Q2 2026 · Jan 31, 2026 −$15.42M
Net Income Q2 2026 · Jan 31, 2025 −$6.29M
Net Income Q2 2026 · Jan 31, 2025 −$12.09M
Operating Income Q2 2026 · Jan 31, 2026 −$7.53M
Operating Income Q2 2026 · Jan 31, 2026 −$15.85M
Operating Income Q2 2026 · Jan 31, 2025 −$7.17M
Operating Income Q2 2026 · Jan 31, 2025 −$12.32M
Short Term Investments Q2 2026 · Jul 31, 2025 $7.37M